This report was first published by Endpoints News. To see the original version, click here
GSK is further delving into the cardiometabolic space — and deepening its relationship with China biotechs — in a $1 billion biobucks deal with an siRNA startup.
The UK pharma is teaming with Suzhou-based SiranBio, the little-known drug developer said Wednesday. GSK is picking up rights to SA030, an siRNA in Phase 1 for obesity, for $55 million upfront, a GSK spokesperson confirmed. The large drugmaker will gain the exclusive rights outside of China, Hong Kong, Macau and Taiwan.
您已阅读14%（572字），剩余86%（3653字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。